EMDACEndocrinologic and Metabolic Drugs Advisory Committee (US FDA)
EMDACEMS (Emergency Medical Services) Medical Directors Association of California
EMDACEast Midlands Dog Agility Club (UK)
References in periodicals archive ?
The discussion during the EMDAC meeting is "an important reminder that there is an unmet need to provide benefits beyond [hemoglobin] [A.
The US FDA's EMDAC Committee voted 13 to 3 (with no abstentions) that the companies had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
M2 PHARMA-June 10, 2015-Sanofi and Regeneron Pharmaceuticals wins US FDA's EMDAC recommendation for the approval of investigational therapy Praluent Injection in reducing LDL-C